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Abstract
Excess reactive oxygen species (ROS) formation can trigger various pathological conditions such as inflammation, in
which xanthine oxidase (XO) is one major enzymatic source of ROS. Although XO has been reported to play
essential roles in inflammatory conditions, the molecular mechanisms underlying the involvement of XO in
inflammatory pathways remain unclear. Febuxostat, a selective and potent inhibitor of XO, effectively inhibits not only
the generation of uric acid but also the formation of ROS. In this study, therefore, we examined the effects of
febuxostat on lipopolysaccharide (LPS)-mediated inflammatory responses. Here we show that febuxostat suppresses
LPS-induced MCP-1 production and mRNA expression via activating MAPK phosphatase-1 (MKP-1) which, in turn,
leads to dephosphorylation and inactivation of JNK in macrophages. Moreover, these effects of febuxostat are
mediated by inhibiting XO-mediated intracellular ROS production. Taken together, our data suggest that XO
mediates LPS-induced phosphorylation of JNK through ROS production and MKP-1 inactivation, leading to MCP-1
production in macrophages. These studies may bring new insights into the novel role of XO in regulating
inflammatory process through MAPK phosphatase, and demonstrate the potential use of XO inhibitor in modulating
the inflammatory processes.
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Introduction
Inflammation plays a fundamental role in a variety of chronic
diseases such as atherosclerosis, rheumatoid arthritis, and
chronic obstructive lung disease [1-3]. During inflammation,
activated macrophages release pro-inflammatory cytokines that
amplify cellular responses to injury as well as generating
reactive oxygen species (ROS), which play an important role in
the defense against invading organisms [4]. However, excess
ROS production by activated cells can also provoke
inflammation and tissue damage.
Xanthine oxidase (XO) is one of the major enzymatic
sources of ROS. It is derived from xanthine dehydrogenase
(XDH) either by proteolytic modification or reversible sulfhydryl
oxidation [5]. XO catalyzes the oxidation of purine substrates,
such as xanthine and hypoxanthine, producing uric acid and
ROS [5]. XO has been reported to be up-regulated by various
inflammatory stimuli such as LPS, hypoxia, and cytokines [6-9].
Augmented XO eventually causes excess ROS formation,
leading to tissue damage. Pharmacological inhibitors of XO,
such as febuxostat, allopurinol and oxypurinol have been
reported to have an anti-inflammatory effect in various
diseases such as atherosclerosis, chronic heart failure, acute
lung injury, renal interstitial fibrosis and ischemic-reperfusion
injury [10-15]. Thus, these findings demonstrate the essential
role of XO in inflammatory conditions. However the
mechanisms that link XO production to inflammation are not
well understood.
We have studied the effects of modulating XO activity by
LPS, in particular its effects on MCP-1, a potent chemotactic
factor for monocytes and dendritic cells, and investigated if
inhibition of XO leads to an altered inflammatory response.
LPS is a main component of the outer membrane of Gram-
negative bacteria, and previous studies have demonstrated
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that LPS up-regulates XO expression and activity.
Pharmacological inhibition of XO protects against LPS-induced
tissue injury [6,7]. Febuxostat, is a potent and selective XO
inhibitor that effectively inhibits the formation of uric acid [16].
In this study, we found that febuxostat significantly suppresses
LPS-induced MCP-1 production in macrophages and mice.
These inhibitory effects were mediated by decreasing ROS
formation and activating MKP-1, which leads to
dephosphorylation and inactivation of JNK. These results may
bring new insights into the novel role of XO in regulating
inflammatory process through MAPK phosphatase.
Materials and Methods
Cell Culture
Human monocytic leukemia cell line THP-1 (TIB-202) was
obtained from American Type Culture Collection and
maintained in RPMI1640 (Life Technologies, Carlsbad, CA)
supplemented with 10% FBS (Thermo Fisher Scientific Inc.,
Waltham, MA), 100 U/mL penicillin, and 100 mg/mL
streptomycin (Life Technologies). To induce the differentiation
into macrophage phenotype, cells were cultured for 72 h in
RPMI1640 supplemented with 200 nM phorbol 12-myristate 13-
acetate (PMA; Sigma-Aldrich, St. Louis, MO), 1% FBS, 100
U/mL penicillin, and 100 mg/mL streptomycin. For human
primary monocyte-derived macrophages, CD14-positive
monocytes from peripheral blood were purchased from
PromoCell (Heidelberg, Germany). To induced the
differentiation into M1 or M2 macrophages, monocytes were
cultured for 7 days in RPMI-1640 supplemented with 50 ng/mL
recombinant GM-CSF or M-CSF, respectively (PromoCell),
10% FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin.
Differentiated macrophages were pretreated for 10 min with the
indicated concentration of febuxostat, allopurinol, oxypurinol or
N-acetyl-L-cysteine (NAC; Sigma-Aldrich), and then stimulated
with 100 ng/mL LPS from Escherichia coli (serotype O111:B4,
Sigma-Aldrich). Cell viability was measured using the WST-8
cell counting kit (DOJINDO, Japan) according to
manufacturer’s instructions.
In vivo experiments
Female C57BL/6 mice (from Charles River) between 8-12
weeks of age were used for experiments. Animal experiments
were performed in strict accordance to the Swiss Federal
Regulations. The protocol was approved by the “Service de la
consommation et des affaires vétérinaires du Canton de Vaud”,
Switzerland. All efforts were made to minimize suffering and
minimize the number of mice needed to assess statistical
significance and experimental reproducibility. Mice were
intraperitoneally treated with 0.5 ml of febuxostat at 1 mM or an
equal volume of vehicle (0.6% DMSO) 30 min before an intra-
peritoneal dose of 300 µg LPS (Escherichia coli O111:B4) in
0.5 ml sterile phosphate buffered saline (PBS). In addition
control mice injected with vehicle or febuxostat alone were
performed. After 6 hours, blood was collected and mice were
euthanized by CO2 administration and peritoneal exudate cells
were subsequently harvested by performing lavage with 3 ml of
PBS. Lavage fluids were centrifuged at 450g for 10 min.
Supernatants of lavage fluids and sera were used for MCP-1
ELISA measurement.
Quantitative real-time RT-PCR (qRT-PCR)
Total RNA was extracted using TRIzol reagent (Life
Technologies) according to the manufacturer’s instructions,
and converted to cDNA using SuperScript VILO MasterMix
(Life Technologies). The cDNA was amplified using SYBR®
Green (Life Technologies) with gene-specific primers on ABI
PRISM 7500 system (Life Technologies). The oligonucleotide
primers were: human MCP-1, 5’-
CTCAGCCAGATGCAATCAAT-3’ and 5’-
TCCTGAACCCACTTCTGCTT-3’; human TNF-α, 5’-
CGAACATCCAACCTTCCCAA-3’ and
CCCCAATTCTCTTTTTGAGCC-3’; human XDH/XO, 5’-
GTGGATGCTGTGGAGGAGAT-3’ and 5’-
TGCTTCCGAGGAGTGTCTTT-3’; human 18S rRNA, 5’-
CGGCTACCACATCCAAGGAA-3’ and 5’-
GCTGGAATTACCGCGGCT-3’. For data normalization, an
endogenous control (18S rRNA) was determined for controlling
the cDNA input and the relative units were calculated by a
comparative Ct method.
Knockdown of XO gene with siRNA
THP-1 cells were treated for 48 h with 200 nM PMA, and
transfected with 50 and 100 nM of control siRNA or human XO
siRNA using DharmaFECT 2 (Thermo Fisher Scientific Inc.).
Then, cells were treated with 100 ng/mL LPS for 20 h. On-
TARGET plus SMART pool siRNA against human XO and non-
targeting control siRNA were purchased from Thermo Fisher
Scientific Inc.. Four target sequences in human XO are 5’-
AGAGUGAGGUUGACAAGUU-3’, 5’-
GGAGUAACAUAACUGGAAU-3’, 5’-
UAGAGGAGCUACUAUUC-3’ and 5’-
ACACGGAGAUUGGCAUUGA-3’.
ELISA
The concentration of MCP-1 protein in culture media was
measured with human MCP-1 DuoSet ELISA kit (R&D
systems, Minneapolis, MN). The concentrations of MCP-1
protein in peritoneal lavage and serum were measured with
mouse MCP-1 (eBioscience, San Diego, CA).
Western blotting
Whole cell lysate was prepared and equal amount of lysate
was loaded into SDS-PAGE. Western blotting was carried out
using antibodies against phospho-JNK (81E11, Cell Signaling
Technology, Beverly, MA), phospho-p38 (D3F9, Cell Signaling
Technology), total IκB-α (L35A5, Cell Signaling Technology),
and β-actin (AC-15, Sigma-Aldrich).
Measurement of intracellular ROS level
Differentiated THP-1 cells were loaded for 30 min with 5 µM
H2DCFDA (Life Technologies), and washed twice with HEPES-
buffered saline (Life Technologies). Then, cells were pretreated
for 10 min with the indicated concentration of febuxostat,
allopurinol, oxypurinol or NAC, and stimulated with 100 ng/mL
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LPS in HBSS. Fluorescent intensity on 488 nm (excitation) and
530 nm (emission) was measured with Paradigm fluorescent
plate reader (Molecular devices, Silicon Valley, CA).
Measurement of ROS level produced by XO/xanthine
Buttermilk XO (Merck Millipore, Billerica, MA) was incubated
for 60 min with 100 µM of xanthine, and ROS levels in the
solutions were measured using the DCF indicator of Oxiselect™
in vitro ROS/RNS assay kit (Cell Biolabs, Inc., San Diego, CA)
according to manufacturer’s instructions.
Measurement of XO activity
Cells were homogenized with 50 mM phosphate buffer
containing protease inhibitor cocktail, and sonicated for 10 min.
The homogenate was incubated with 5 µM of pterine (Sigma-
Aldrich) for 60 min, and fluorescent intensity on 360 nm
(excitation) and 400 nm (emission) was measured with
Paradigm fluorescent plate reader.
Measurement of MKP-1 activity
Cell lysates were immunoprecipitated with anti-MKP-1
antibody (C-19, Santa Cruz Biotechnology, Inc., Santa Cruz,
CA), and the phosphatase activities in the immunoprecipitates
were determined with 6,8-fifluoro-4-methylumbelliferyl
phosphate (Life Technologies). Fluorescent intensity on 360
nm (excitation) and 455 nm (emission) was measured with
Paradigm fluorescent plate reader.
Statistical analysis
All data are expressed as mean±SEM. For two-group
comparisons, student’s t test was used. For multiple
comparisons, one-way ANOVA followed by a Dunnett’s test
was used to compare each group versus a vehicle-treated
group. In time-dependent experiments, two-way ANOVA was
used for two-group comparisons and Bonferroni test was used
for comparisons at each time point. All data were statistically
analyzed using GraphPad PRISM software version 4.01
(GraphPad, La Jolla, CA). Differences with a probability value
of <0.05 were considered significant.
Results
Febuxostat inhibits LPS-induced XO activity and
intracellular ROS formation in PMA-treated THP-1 cells
In this study, we first examined whether LPS enhanced XO
activity and whether febuxostat inhibits LPS-induced XO
activity and intracellular ROS formation. PMA-treated THP-1
cells were stimulated with 100 ng/mL LPS in the presence or
absence of febuxostat. As shown in Figure 1A, LPS treatment
resulted in the rapid and sustained increase in XO activity
0.25-4 h after treatment. Febuxostat effectively inhibited basal
and LPS-induced XO activity (Figure 1A). In addition, the
analysis using H2DCFDA, an indicator of ROS, showed that
intracellular ROS formation was significantly increased by LPS
treatment in a time-dependent manner (Figure 1B). Febuxostat
inhibited LPS-induced intracellular ROS formation whereas N-
acetyl-L-cysteine (NAC), an antioxidant, deleted intracellular
ROS completely (Figure 1B and 1C). These data demonstrated
that febuxostat inhibits LPS-induced XO activity and XO-
derived intracellular ROS formation.
Febuxostat suppresses LPS-induced MCP-1 production
by inhibiting XO-derived ROS formation in
macrophages and mice
To determine the effects of febuxostat on LPS-induced
inflammatory responses, we examined whether febuxostat
suppresses LPS-induced MCP-1 production in macrophages.
PMA-treated THP-1 cells were pretreated with 30 µM of
febuxostat and then stimulated with 100 ng/mL LPS for 20 h.
Although LPS treatment resulted in a large amount of MCP-1 in
the supernatant, febuxostat significantly and dose-dependently
inhibited LPS-induced production of MCP-1 without any effect
on cytotoxicity (Figure 2A and 2B). NAC also inhibited LPS-
induced production of MCP-1. Additionally, in human primary
monocyte-derived M1 and M2 macrophages, febuxostat also
suppressed MCP-1 production induced by LPS (Figure S1 in
File S1). To confirm the inhibitory effect of febuxostat was
dependent on the inhibition of XO, we tested whether XO
siRNA, as well as febuxostat, suppressed LPS-induced MCP-1
production. XO knockdown mediated by XO siRNA but not
control siRNA resulted in the inhibition of LPS-induced MCP-1
production (Figure 2C and S2 in File S1). Taken together,
these results demonstrated that febuxostat suppresses LPS-
induced MCP-1 production through inhibiting XO-derived ROS
formation in macrophages.
Furthermore, we examined whether febuxostat also inhibits
LPS-induced MCP-1 secretion in a in vivo model. Mice were
intraperitoneally treated with febuxostat, then after 30 min mice
were injected with 300 µg of LPS. In vehicle-treated mice,
robust increases in MCP-1 levels were observed in peritoneal
lavage whereas MCP-1 levels in febuxostat-treated mice were
significantly reduced compared to vehicle-treated mice (Figure
2D). Similar data were obtained in serum from vehicle- and
febuxostat-treated mice (vehicle: 98001±8624, febuxostat:
72545±7279, p<0.05). These data demonstrated that
febuxostat inhibits LPS-induced MCP-1 production not only in a
in vitro cell system but also in a in vivo mice model.
Febuxostat suppresses LPS-induced MCP-1 mRNA
expression without affecting mRNA stability
Next, we examined whether febuxostat inhibits LPS-induced
MCP-1 mRNA expression in PMA-treated THP-1 cells. LPS
treatment results in the increase in MCP-1 mRNA expression in
a time-dependent manner whereas febuxostat suppressed
LPS-induced MCP-1 mRNA expression (Figure 3A). Consistent
with the effects on protein level in Figure 2A, febuxostat
significantly inhibited the induction of MCP-1 mRNA by LPS in
a dose-dependent manner (Figure 3B). In addition, LPS-
induced TNF-α expression was also inhibited by febuxostat
(Figure S3 in File S1). Inhibitory effects of febuxostat were
observed 2 h after LPS treatment, suggesting that febuxostat
affected the transcription of MCP-1 mRNA. We next tested
whether febuxostat affected the stability of MCP-1 mRNA. As
shown in Figure 3C, febuxostat failed to affect the stability of
MCP-1 mRNA. These results suggest that febuxostat inhibits
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Figure 1.  Febuxostat inhibits LPS-induced XO activity and intracellular ROS formation in PMA-treated THP-1 cells.  (A)
PMA-treated THP-1 cells were stimulated for the indicated time with 100 ng/mL LPS in the absence or presence of 30 µM
febuxostat. The cell homogenates were incubated with 5 µM pterine for 60 min, and fluorescence intensity was measured. Data are
shown as mean (n=3). (B) PMA-treated THP-1 cells were loaded for 30 min with 5 µM H 2DCFDA, and then stimulated for the
indicated times with 100 ng/mL LPS in the absence or presence of febuxostat (30 µM) or NAC (10 mM). Fluorescence intensity was
measured. Data of one representative experiment (out of three experiments) are shown as mean±SEM (n=4). $P<0.01, # P<0.001
versus control-group, **P<0.001 versus vehicle/LPS-treated group. (C) Cells were loaded for 30 min with 5 µM H2DCFDA, and then
stimulated for 60 min with 100 ng/mL LPS in the absence or presence of febuxostat (0.03, 0.1, 0.3, 1, 3, 10 and 30 µM) or NAC (10
mM). Fluorescence was measured and expressed as fluorescence intensity over LPS-untreated group. Data of one representative
(out of three experiments) are shown as mean±SEM (n=4). #P<0.001 versus control-group, **P<0.01 versus vehicle/LPS-treated
group.
doi: 10.1371/journal.pone.0075527.g001
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LPS-induced MCP-1 mRNA expression without affecting
mRNA stability, and regulates the transcription of MCP-1 by
LPS.
Febuxostat suppresses LPS-induced ROS formation
and MCP-1 production more effectively than allopurinol
and oxypurinol
It has been reported that other XOR inhibitors such as
allopurinol and oxypurinol suppress intracellular ROS formation
by XO, but their inhibitory effects are less potent than that of
febuxostat [17]. Febuxostat (100 nM) potently inhibited ROS
production by cell free XO/xanthine system, whereas the
inhibitory effects of allopurinol or oxypurinol were partial, even
at 1000-fold concentrations of febuxostat (Figure 4A). Similarly,
in PMA-treated THP-1 cells allopurinol or oxypurinol had very
weak or no inhibitory effects on LPS-induced intracellular ROS
(Figure 4B). Consistent with these results, allopurinol or
oxypurinol did not inhibit LPS-induced MCP-1 production and
mRNA as efficiently as febuxostat (Figure 4C and 4D). These
results indicated that febuxostat inhibits LPS-induced ROS
formation and MCP-1 production more effectively than
allopurinol and oxypurinol.
Figure 2.  Febuxostat suppresses LPS-induced MCP-1 production by inhibiting XO-derived ROS formation in macrophages
and mice.  PMA-treated THP-1 cells were incubated for 20 h with 100 ng/mL LPS in the absence or presence of febuxostat or NAC.
(A) The levels of MCP-1 in the supernatants were measured by ELISA. Data are shown as mean±SEM (n=4) of four independent
experiments performed. #P<0.001 versus control-group, **P<0.01 versus vehicle/LPS-treated group. (B) Cytotoxicity was determined
using WST-8. Data are shown as mean±SEM (n=3) of three independent experiments performed. ns, not significant versus vehicle/
LPS-treated group. (C) PMA-treated THP-1 cells were transfected with 50 or 100 nM of XO siRNA or control siRNA, and then
incubated for 20 h with 100 ng/mL LPS. The levels of MCP-1 in the supernatants were measured by ELISA. Data of one
representative experiment (out of two experiments) are shown as mean±SEM (n=3). #P<0.01 versus 0 nM XO siRNA/control-group,
**P<0.01 versus 0 nM XO siRNA/LPS-treated group. (D) Mice were intraperitoneally treated with 0.5 mL of vehicle (0.6% DMSO) or
febuxostat (1 mM), and then injected with 300 µg of LPS. After 6 h, peritoneal lavage and serum were collected. The levels of
MCP-1 in peritoneal lavage and serum were measured by ELISA. Data are shown as mean±SEM. LPS-treated mice with vehicle:
n=20, with febuxostat: n=18, control mice with vehicle: n=4, and febuxostat: n=4. Value in parentheses indicates mean of MCP-1
concentration. **P<0.01 versus vehicle/LPS-treated group.
doi: 10.1371/journal.pone.0075527.g002
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Figure 3.  Febuxostat suppresses LPS-induced MCP-1 mRNA expression without affecting mRNA stability.  (A) PMA-treated
THP-1 cells were stimulated with 100 ng/mL of LPS for 0, 4 and 16 h in the absence or presence of febuxostat (3, 10 and 30 µM) or
NAC (10 mM). Total RNA was extracted, and qRT-PCR was performed as described in materials and methods. Data are shown as
mean of two independent experiments in which similar results were obtained. (B) Cells were stimulated with 100 ng/mL of LPS for 2
h in the absence or presence of febuxostat (3, 10 and 30 µM) or NAC (10 mM). Total RNA was extracted, and qRT-PCR was
performed as described in materials and methods. Data are shown as mean±SEM (n=3) of three independent experiments.
#P<0.001 versus control-group, **P<0.01 versus vehicle/LPS-treated group. (C) PMA-treated THP-1 cells were stimulated for 4 h
with 100 ng/mL LPS in the absence or presence of febuxostat (30 µM), and then treated with 5 µg/mL Actinomycin D (ActD). Two or
4 h after ActD treatment, total RNA was extracted, and qRT-PCR was performed. Data are shown as mean±SEM (n=3) of three
independent experiments.
doi: 10.1371/journal.pone.0075527.g003
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Febuxostat suppresses LPS-induced activation of JNK
In LPS signaling, activation of transcription factor NF-κB and
MAPKs play essential roles in transcriptional induction of genes
involved in inflammation, such as iNOS, COX-2 and TNF-α
[18]. We therefore sought to investigate whether febuxostat
inhibits signaling pathways, which play important roles in LPS-
mediated MCP-1 induction in macrophages. As shown in
Figure 5A, LPS transiently decreased total IκB-α level, showing
the activation of NF-κB. However, pretreatment with febuxostat
failed to change total IκB-α level. In addition, LPS treatment
resulted in a time-dependent phosphorylation of JNK and p38
(Figure 5A), but not of ERK and MEK1 (data not shown).
Febuxostat suppressed LPS-induced phosphorylation of JNK
but not of p38. To determine the involvement of JNK in LPS-
induced MCP-1, we examined the effects of LPS on MCP-1
production and mRNA expression in the absence or presence
of SP600125, which is the specific inhibitor of JNK. As shown
in Figure 5B and 5C, SP600125 suppressed LPS-induced
MCP-1 production as well as mRNA expression, indicating that
JNK plays essential role in LPS-induced MCP-1 production.
These results suggest that febuxostat suppresses LPS-
mediated activation of JNK.
Figure 4.  Febuxostat suppresses LPS-induced ROS formation and MCP-1 production more effectively than allopurinol and
oxypurinol.  (A) ROS was produced by buttermilk XO (10 mU/mL) and xanthine (100 µM) in the absence or presence of febuxostat
(Feb, 100 nM), allopurinol (Allo, 100 µM) or oxypurinol (Oxy, 100 µM), and detected by DCF ROS indicator. Fluorescence was
measured. Data are shown as mean±SEM (n=3) of three independent experiments. #P<0.0001 versus control-group,***P<0.001
versus vehicle-treated group. (B) PMA-treated THP-1 cells were loaded for 30 min with 5 µM H2DCFDA, and then stimulated for 60
min with 100 ng/mL of LPS in the absence or presence of febuxostat (30 µM), allopurinol (300 µM) oroxypurinol (300 µM).
Fluorescence was measured and expressed as fluorescence intensity over LPS-untreated group. Data of one representative
experiment (out of three experiments) are shown as means ± SEM (n=4). #P<0.001 versus control-group, **P<0.01 versus vehicle/
LPS-treated group. (C) PMA-treated THP-1 cells were incubated for 20 h with 100 ng/mL of LPS in the absence or presence of
febuxostat (30 µM), allopurinol (300 µM) or oxypurinol (300 µM). The levels of MCP-1 in the supernatants were measured by ELISA.
Data of one representative experiment (out of three experiments) are shown as mean±SEM (n=3). #P<0.001 versus control-group,
*P<0.05, ***P<0.001 versus vehicle/LPS-treated group. (D) Cells were stimulated for 16 h with 100 ng/mL of LPS in the absence or
presence of febuxostat (30 µM), allopurinol (300 µM) or oxypurinol (300 µM). Total RNA was extracted, and qRT-PCR was
performed as described in materials and methods. Data are shown as mean±SEM (n=3) of three independent experiments.
**P<0.01, ***P<0.001 versus vehicle/LPS-treated group.
doi: 10.1371/journal.pone.0075527.g004
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Figure 5.  Febuxostat suppresses LPS-induced activation of JNK.  Cells were stimulated with 100 ng/mL LPS in the presence
or absence of febuxostat (30 µM). (A) Western blot analysis using anti-total IκBα, phospho-p38 and phospho-JNK antibodies. Equal
amounts of proteins were loaded. The results are representative of two independent experiments in which similar results were
obtained. (B) PMA-treated THP-1 cells were stimulated for 20 h with 100 ng/mL LPS in the presence or absence of SP600125 (0.3,
3 and 30 µM). The levels of MCP-1 in the supernatants were measured by ELISA. Data of one representative (out of three
experiments) are shown as mean±SEM (n=3). #P<0.001 versus control-group, **P<0.01 versus vehicle/LPS-treated group. (C) Total
RNA was extracted, and qRT-PCR was performed as described in materials and methods. Data are shown as mean±SEM (n=3) of
three independent experiments. #P<0.001 versus control-group, *P<0.05, ***P<0.001 versus vehicle/LPS-treated group.
doi: 10.1371/journal.pone.0075527.g005
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Febuxostat suppresses LPS-induced MCP-1 production
via MKP-1-dependent inhibition of JNK through
increasing MKP-1 activity
Because protein phosphatases have been shown to regulate
the activation of JNK [19], we therefore examined whether
protein phosphatases are involved in febuxostat-mediated
inhibition of JNK phosphorylation. We first evaluated the effects
of febuxostat on LPS-induced phosphorylation of JNK, and
LPS-mediated MCP-1 expression in the presence or absence
of protein phosphatase inhibitors. Here, we determined the
effects of orthovanadate and Ro-31-8220, which are protein
phosphatase inhibitor and MKP-1 inhibitor, respectively. As
shown in Figure 6A, febuxostat-mediated inhibitions of
phosphorylation of JNK were abolished by both orthovanadate
and Ro-31-8220. Febuxostat no longer significantly inhibited
LPS-induced MCP-1 expression in the presence of these
inhibitors (Figure 6B). Moreover, the inhibitory effects of NAC
were also abolished by these inhibitors. These data
demonstrate that febuxostat inhibits LPS-induced MCP-1
expression via MKP-1-dependent inhibition of JNK activation.
Furthermore, we determined whether febuxostat affects the
activity of MKP-1. After LPS treatment, MKP-1 activity was
rapidly decreased, and followed by gradual increase (Figure
6C), suggesting that the change in phosphatase activity after
Figure 6.  Febuxostat suppresses LPS-induced MCP-1 production via MKP-1-dependent inhibition of JNK through
increasing MKP-1 activity.  Cells incubated for 30 min with vanadate (200 µM) or Ro-31-8220 (1 µM) were pretreated for 10 min
with febuxostat (30 µM) or NAC (10 mM), and then stimulated for 1 (A) or 2 h (B) with 100 ng/mL LPS. (A) Western blot analysis
using anti-phospho-JNK and β-actin antibodies. Equal amounts of proteins were loaded. The results are representative of two
independent experiments in which similar results were obtained. (B) Total RNA was extracted, and qRT-PCR was performed as
described in materials and methods. Data are shown as mean±SEM (n=3) of three independent experiments. $P<0.01, # P<0.001
versus control-group, *P<0.05, ***P<0.001 versus vehicle/LPS-treated group. (C) Cells were stimulated with 100 ng/mL of LPS in the
presence or absence of febuxostat (30 µM). MKP-1 activities in immunoprecipitates were measured. Data are shown as mean±SEM
(n=3) of three independent experiments. *P<0.05, ***P<0.001 versus vehicle-treated group. (D) Schema of the signaling pathways
involved in XO-mediated induction of MCP-1 expression by LPS. As indicated, LPS up-regulates MCP-1 expression via JNK-
dependent pathway. XO activated by LPS causes decreased MKP-1 activity via accumulation of intracellular ROS that, in turn,
leads to enhancement of JNK phosphorylation, the positive regulator of MCP-1 expression. Febuxostat suppresses LPS-induced
MCP-1 expression through inhibiting XO/ROS/MKP-1/JNK pathway.
doi: 10.1371/journal.pone.0075527.g006
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LPS treatment was likely to affect the phosphorylation levels of
JNK. Consistent with time points at which febuxostat-mediated
inhibition of JNK activation was observed, febuxostat
significantly increased phosphatase activity 1-2 hours after LPS
treatment (Figure 6C). Taken together, these results suggested
that febuxostat suppresses LPS-induced MCP-1 production via
MKP-1-dependent inhibition of JNK through increasing MKP-1
activity.
Discussion
Although several studies have reported that XO plays the
fundamental roles in inflammation, the molecular mechanisms
underlying the involvement of XO in inflammatory responses
remain unclear. We here examined the effects of febuxostat, a
selective and potent inhibitor of XO, on LPS-induced
inflammatory signals. In this study, we found that febuxostat
significantly suppresses LPS-induced MCP-1 production in
human macrophages and in vivo in mice (Figure 2 and Figure
S1 in File S1). The inhibitory effects of febuxostat on LPS-
induced MCP-1 were mimicked by XO knockdown (Figure 2C),
as well as the other XO inhibitors such as allopurinol and
oxypurinol (Figure 4C). In addition, exogenous XO induced
febuxostat-inhibitable MCP-1 production in PMA-treated THP-1
cells (Figure S4 in File S1). Taken together, these data
suggested that XO plays essential roles in LPS-induced MCP-1
production, and that our in vitro system using PMA-treated
THP-1 cells is well suitable for investigating the mechanisms
underlying XO-mediated inflammatory pathways.
MKP-1, a protein phosphatase with dual specificity (Ser/Thr
or Thr/Tyr), is responsible for the inactivation of JNK and p38,
and therefore controls MAPK-dependent inflammation during
the innate immune response [20,21]. Because MKP-1 activity
has reported to be regulated by oxidative stress [22], we
hypothesized that XO-derived ROS might contribute to
decreased MKP-1 activity following LPS stimulation.
Supporting this hypothesis, NAC-mediated inactivation of JNK
was abolished by orthovanadate or Ro-31-8220 (Figure 6A),
and decrease in MKP-1 activity by LPS was recovered by NAC
(data not shown). Thus, LPS decreases MKP-1 activity via XO-
derived ROS, leading to enhancement of JNK phosphorylation
and ultimately to the induction of MCP-1. On the other hand,
febuxostat inhibits XO-derived ROS and increases MKP-1
activity, which leads to dephosphorylation and inactivation of
JNK. This is supported by the findings that febuxostat failed to
inhibit LPS-induced MCP-1 production and phosphorylation of
JNK in the presence of orthovanadate or Ro-31-8220 (Figure
6A and 6B). Additionally, febuxostat enhanced MKP-1 mRNA
levels, whereas it did not alter the mRNA levels of the other
MKPs, such as MKP-3 and -5 (data not shown). To our
knowledge, this is the first report showing a link between XO
and MKP-1, representing an important and new regulatory
mechanism in inflammation.
XO is well known to produce not only ROS but also uric acid.
Several studies have reported that uric acid induced MCP-1
production in tubular epithelial cells, adipocytes and vascular
smooth muscle cells [23-25]. However, our data revealed that
XO-derived ROS is involved in LPS-induced MCP-1 production
in PMA-treated THP-1 cells. In fact, LPS enhanced XO activity
and increased intracellular ROS formation (Figure 1). In
addition, febuxostat as well as NAC attenuated increases in
ROS formation and MCP-1 production (Figures 1 and 2).
Furthermore, uric acid at concentrations equivalent to that
found in hyperuricemic blood failed to affect basal and LPS-
induced MCP-1 levels (Figure S5 in File S1). Taken together,
these findings demonstrate the crucial role of ROS in LPS-
induced MCP-1 production in macrophages.
Inhibitory effects of febuxostat on the expression of
cytokines/chemokines were selective: febuxostat also inhibited
LPS-induced TNF-α, VCAM-1 and MMP9 expression, as well
as MCP-1, but did not affect IL-8 (Figure S3 in File S1 and data
not shown). Additionally, inhibitory profiles of febuxostat did not
completely correspond to that of SP600125 (data not shown),
suggesting the possible involvement of signal molecules other
than JNK in XO-mediated inflammatory responses. Further
studies are required to clarify this possibility.
The inhibitory effect of febuxostat against LPS-induced
MCP-1 production obtained in the human THP-1 cell line was
reproduced in human primary macrophages. In both cell types,
the IC50 dose was close to 10 µM. It is interesting to note that
in clinical studies when febuxostat was given at 120 mg once
daily for 13 days, the Cmax of febuxostat in plasma is around 17
µM [26,27]. Thus, the inhibitory doses of febuxostat in vitro are
in the same range of the doses found in plasma from
febuxostat-treated patients, suggesting that the anti-
inflammatory effects of febuxostat found in vitro may be
relevant in vivo. Further clinical studies are needed to confirm
the potential anti-inflammatory role of XO inhibiotrs.
In conclusion, febuxostat suppresses LPS-induced MCP-1
production and mRNA expression via activation of MKP-1
which, in turn, leads to dephosphorylation and inactivation of
JNK in macrophages. These findings suggest that XO
contributes to inflammatory responses via MKP-1-dependent
JNK activation through intracellular ROS formation. These
studies may bring new insights into a novel role of XO in
regulating inflammatory process through MAPK phosphatase,
and demonstrate the potential use of XO inhibitor in modulating
the inflammatory processes.
Supporting Information
File S1.  Supporting figures (Figures S1-S5). Figure S1.
Human primary monocyte-derived macrophages were
differentiated from CD14-positive monocytes with 50 ng/mL
GM-CSF or M-CSF for 7 days, then stimulated with 15.6 ng/mL
LPS in the absence or presence of febuxostat. The levels of
MCP-1 in the supernatants were measured by ELISA. Data are
shown as mean of two independent experiments in which
similar results were obtained. Figure S2. PMA-treated THP-1
cells were transfected with 50 or 100 nM of XO siRNA or
control siRNA, and then incubated for 20 h with 100 ng/mL
LPS. Total RNA was extracted from 3 wells, and qRT-PCR was
performed as described in materials and methods. Data are
shown as mean of two independent experiments in which
similar results were obtained. Figure S3. PMA-treated THP-1
cells were stimulated with 100 ng/mL of LPS for 2 h in the
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absence or presence of febuxostat (3, 10 and 30 µM) or NAC
(10 mM). Total RNA was extracted, and qRT-PCR was
performed as described in materials and methods. Data are
shown as mean±SEM (n=3) of three independent experiments.
#P<0.001 versus control-group, *P<0.05, **P<0.01 versus
vehicle/LPS-treated group. Figure S4. PMA-treated THP-1
cells were stimulated with 10 mU/mL of XO for 20 h in the
absence or presence of febuxostat (10 µM). The levels of
MCP-1 in the supernatants were measured by ELISA. Data are
shown as mean of two independent experiments in which
similar results were obtained. Figure S5. PMA-treated THP-1
cells were stimulated with 100 ng/mL of LPS for 20 h in the
absence or presence of uric acid (0, 500 and 1000 µM). The
levels of MCP-1 in the supernatants were measured by ELISA.
Data are shown as mean±SEM (n=3).
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